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Abstract:  
Introduction
Association between aplastic anemia (AA) and lymphoid neoplasms is unusual and represent a challenge. We do not yet
know whether there is causality in this association or simply coincidence. Data related to frequency, diagnosis and
management of patients with such an association are lacking. The SAAWP of the EBMT aimed to collect information of
patients with AA and a lymphoid neoplasm according two-step procedures.
 
Material and methods
First, a search for this association was performed within the registry of the EBMT.  Patients who developed either AA or
lymphoma after hematopoietic stem cell transplantation (HSCT) were excluded for this analysis, because bone marrow
failures emerging after HSCT may represent the loss of the graft, and the occurrence of a lymphoma after HSCT
represents a complication of the transplantation, the so-called post-transplant lymphoproliferative disorder. Both
situations do not belong to the scope of this study.
 
In a second step, centers who reported a case were asked for more detailed information concerning type of therapy and
outcome for each disease. Since we hypothesize an underreporting of such association in non-severe AA, centers




So far, we detected 8 cases reported by 7 different centers (202=1; 205=1; 231=1; 253=2; 539=1; 565=1 and 590=1)
from 6 different countries within the EBMT registry. Four patients were treated with HSCT after both diagnoses, and 4
patients were treated with immunosuppression therapy (IST) for AA. In 5 cases the AA was the first diagnosis, and
lymphoma was diagnosed afterwards. Time between both diagnoses was shorter than 1 year in three cases (4, 9 and 11
months), and longer in 2 cases (36 and 84 months). Three cases had an initial diagnosis of lymphoma and many years
later developed AA (4, 12 and 36 years). All 8 patients were diagnosed with a non-Hodgkin lymphoma (diffuse large B-
cell lymphoma=3; follicular lymphoma=1, without further information available= 4). Patients treated with IST had a median
survival of 81 months (54-123), all were alive with remission of both diseases at last control. 3 out of 4 patients who
underwent an allogeneic HSCT were alive and in remission for both diseases at last control, median survival post-HSCT
was 20 months (3-45).
 
Conclusions
This very preliminary data confirm the uncommon association between AA and lymphoid neoplasms. This is an ongoing
study, data collection will continue until February 2015, an extended up-dated analysis will be presented during the 41th
Annual Meeting of EBMT.
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